Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.
The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...
Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST ...
Wendy’s plans to close hundreds of US restaurants over the next few months in an effort to boost its profit. The Dublin, Ohio ...
18h
US digest: Nvidia rebounds ahead of rarnings, Apple delays new iPhone Air, Trump eyes debt paydown
US stocks rose Monday as Nvidia led tech gains, Apple delayed the iPhone Air, Pfizer acquired Metsera, and Trump unveiled a ...
Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...
Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...
Zacks Investment Research on MSN
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
1d
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...
At Celosphere 2025, six enterprise leaders from Pfizer, Deutsche Telekom, DHL, Standard Bank, Metro Bank, and NN Bank ...
Novo Nordisk shares rose Monday after the Danish drugmaker withdrew from a bidding war with Pfizer for U.S. obesity drug maker Metsera. Shares climbed as much as 3.5% in early European trade. Pfizer ...
Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback